Advisory Services Network LLC Sells 291 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Advisory Services Network LLC lowered its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 1.4% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 20,126 shares of the medical equipment provider’s stock after selling 291 shares during the quarter. Advisory Services Network LLC’s holdings in Intuitive Surgical were worth $6,790,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. Provence Wealth Management Group bought a new position in Intuitive Surgical in the 4th quarter valued at $276,000. Portside Wealth Group LLC lifted its stake in Intuitive Surgical by 8.2% in the fourth quarter. Portside Wealth Group LLC now owns 816 shares of the medical equipment provider’s stock worth $275,000 after purchasing an additional 62 shares during the last quarter. Sequoia Financial Advisors LLC lifted its stake in Intuitive Surgical by 58.0% in the fourth quarter. Sequoia Financial Advisors LLC now owns 8,315 shares of the medical equipment provider’s stock worth $2,805,000 after purchasing an additional 3,054 shares during the last quarter. Kades & Cheifetz LLC bought a new stake in Intuitive Surgical in the fourth quarter worth $230,000. Finally, Blair William & Co. IL lifted its stake in Intuitive Surgical by 3.1% in the third quarter. Blair William & Co. IL now owns 377,371 shares of the medical equipment provider’s stock worth $110,302,000 after purchasing an additional 11,400 shares during the last quarter. Institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Trading Up 1.6 %

ISRG stock traded up $6.46 during midday trading on Friday, reaching $404.85. 1,082,160 shares of the company’s stock traded hands, compared to its average volume of 1,036,880. The stock’s 50-day moving average is $386.45 and its 200 day moving average is $362.07. The stock has a market cap of $143.60 billion, a P/E ratio of 73.08, a PEG ratio of 5.15 and a beta of 1.39. Intuitive Surgical, Inc. has a 52-week low of $254.85 and a 52-week high of $408.43.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.10. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The company had revenue of $1.89 billion during the quarter, compared to analysts’ expectations of $1.87 billion. During the same period last year, the company posted $1.00 earnings per share. Intuitive Surgical’s quarterly revenue was up 11.5% on a year-over-year basis. As a group, research analysts expect that Intuitive Surgical, Inc. will post 4.8 EPS for the current fiscal year.

Insider Buying and Selling at Intuitive Surgical

In other news, VP Marshall Mohr sold 108,790 shares of the firm’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $385.08, for a total value of $41,892,853.20. Following the completion of the sale, the vice president now owns 26,877 shares in the company, valued at approximately $10,349,795.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, EVP Robert Desantis sold 1,498 shares of Intuitive Surgical stock in a transaction that occurred on Friday, April 26th. The shares were sold at an average price of $369.92, for a total value of $554,140.16. Following the transaction, the executive vice president now owns 5,507 shares of the company’s stock, valued at approximately $2,037,149.44. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Marshall Mohr sold 108,790 shares of Intuitive Surgical stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $385.08, for a total transaction of $41,892,853.20. Following the completion of the transaction, the vice president now directly owns 26,877 shares in the company, valued at approximately $10,349,795.16. The disclosure for this sale can be found here. Insiders sold 148,290 shares of company stock worth $57,207,154 over the last 90 days. 0.90% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on ISRG. StockNews.com cut shares of Intuitive Surgical from a “buy” rating to a “hold” rating in a research report on Thursday, February 29th. BTIG Research upped their price objective on shares of Intuitive Surgical from $412.00 to $421.00 and gave the stock a “buy” rating in a report on Friday, April 19th. Stifel Nicolaus upped their price objective on shares of Intuitive Surgical from $420.00 to $430.00 and gave the stock a “buy” rating in a report on Monday, April 8th. Jefferies Financial Group upped their target price on shares of Intuitive Surgical from $365.00 to $375.00 and gave the stock a “hold” rating in a research note on Friday, April 19th. Finally, Citigroup upped their target price on shares of Intuitive Surgical from $428.00 to $462.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Five equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $396.17.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.